--- title: "A Look At Riverstone Holdings (SGX:AP4) Valuation After Softer Q1 2026 Earnings Results" type: "News" locale: "en" url: "https://longbridge.com/en/news/287388036.md" description: "Riverstone Holdings (SGX:AP4) reported Q1 2026 sales of MYR 214.3 million and net income of MYR 41.1 million, both down from last year. Despite this, the stock has risen 22.88% in 30 days and 45.61% over the year. With a P/E ratio of 22.4x, it appears undervalued compared to peers. However, reliance on glove demand cycles poses risks to its recovery. The DCF model suggests a fair value of S$1.71 per share, indicating a 45% discount." datetime: "2026-05-22T16:20:55.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287388036.md) - [en](https://longbridge.com/en/news/287388036.md) - [zh-HK](https://longbridge.com/zh-HK/news/287388036.md) generator: "portal-rs" --- # A Look At Riverstone Holdings (SGX:AP4) Valuation After Softer Q1 2026 Earnings Results Riverstone Holdings (SGX:AP4) has released its Q1 2026 results, reporting sales of MYR 214.3 million and net income of MYR 41.1 million, both lower than in the same quarter a year earlier. See our latest analysis for Riverstone Holdings. Despite softer Q1 results, Riverstone Holdings' share price has shown strong momentum, with a 30 day share price return of 22.88% and a 1 year total shareholder return of 45.61%, signalling improving sentiment around its recovery profile. If this recent move has you thinking about other opportunities in healthcare, it could be a good moment to scan the market for 125 healthcare AI stocks With earnings softer but the stock up sharply and trading at a discount to both the analyst target and an estimated intrinsic value, is Riverstone still undervalued, or are investors already paying up for future growth? ## Price-to-Earnings of 22.4x: Is it justified? On a P/E of 22.4x at a last close of S$0.94, Riverstone looks cheap relative to both its sector peers and an estimated fair earnings multiple. The P/E ratio compares the current share price with earnings per share, so it effectively shows how much you are paying for each unit of profit. For a healthcare glove manufacturer with an established global customer base, this is a useful shorthand for how the market is weighing its current earnings and the profit outlook. Here, the stock is described as good value versus the Asian Medical Equipment industry average P/E of 25.7x and the peer average of 34.7x. It also screens as good value versus an estimated fair P/E of 33.1x. Explore the SWS fair ratio for Riverstone Holdings **Result: Price-to-Earnings of 22.4x (UNDERVALUED)** However, softer Q1 earnings and reliance on glove demand cycles could challenge the recovery story if pricing or order volumes weaken from this point. Find out about the key risks to this Riverstone Holdings narrative. ## Another View: What Does The Cash Flow Model Say? While the P/E of 22.4x suggests Riverstone looks cheap versus peers and a fair ratio of 33.1x, the SWS DCF model points to an estimated value of S$1.71 per share, implying the stock trades at about a 45% discount. If both earnings and cash flow lenses hint at value, what might the market be pricing in? Look into how the SWS DCF model arrives at its fair value. Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Riverstone Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 228 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. ## Next Steps With the market split between concern over risks and interest in the recovery story, it may be useful to move quickly and test the numbers yourself by reviewing the 3 key rewards and 1 important warning sign ## Looking for more investment ideas? If this earnings update sharpened your thinking, do not stop here. Broaden your watchlist now so you are not reacting after the market has already moved. - Explore 224 elite penny stocks with strong financials to find companies that combine smaller size with stronger fundamentals than many peers. - Focus on value by reviewing 228 high quality undervalued stocks that pair solid cash generation with balance sheets that support their current pricing. - Consider 311 resilient stocks with low risk scores that carry more resilient risk scores and may help smooth overall volatility in a portfolio. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### Related Stocks - [AP4.SG](https://longbridge.com/en/quote/AP4.SG.md) ## Related News & Research - [Is UMS Integration (SGX:558) Fully Valued On Strong Q2 2026 Earnings?](https://longbridge.com/en/news/296052225.md) - [ComfortDelGro (SGX:C52) Reports Mixed Half Year Earnings, Is It Trading Below Fair Value?](https://longbridge.com/en/news/296348791.md) - [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/296518280.md) - [How Investors Are Reacting To Haw Par (SGX:H02) Earnings And EPS Declines In First Half 2026](https://longbridge.com/en/news/296052226.md) - [Apple declares Q3 2026 distribution of R$ 0.05 per unit, payable Aug. 19](https://longbridge.com/en/news/296137926.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**